Is Cabergoline safe to breastfeed?

Cabergoline (Cabergoline) is a dopamine receptor agonist commonly used to treat conditions with abnormally high dopamine levels, such as pituitary tumors and hyperprolactinemia. Although cabergoline is sometimes used in some circumstances to reduce symptoms of breast engorgement and lactation in women after childbirth, it is not a routine milk-returning medication and requires careful consideration before use.

The use of cabergoline should be under the supervision of a doctor and strictly in accordance with the doctor's instructions. Its safety and effectiveness will vary among individuals and should not be used at discretion. In addition, cabergoline may cause a range of side effects, including headache, nausea, vomiting, hypotension, and changes in mental status. Women may respond differently to the metabolism and excretion of the drug during lactation, especially in the postpartum period, and must therefore be used with caution.

In addition, cabergoline is not a traditional milk-returning drug. If a woman needs to resume breastfeeding, she should first explore other, more common and safer methods, such as gradually reducing the number of breastfeeds, maintaining adequate fluid intake, taking appropriate diet and rest, and consulting a professional healthcare provider for more advice and support regarding breastfeeding.

In short, cabergoline should be used with caution and under the guidance of a doctor. Women should carefully weigh the risks and benefits before considering using this drug to ensure safety and effectiveness, while exploring other feasible methods of milk return to ensure the health of mother and baby.

Cabergoline is not currently available in the country, so patients cannot purchase it domestically and need to purchase cabergoline through overseas channels. In foreign countries, cabergoline is the original drug, and the cheaper version is the Turkish original drug, which costs about one to two hundred yuan.